Research Topics
| A L PotoskySummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Breast cancer survival and treatment in health maintenance organization and fee-for-service settingsA L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
J Natl Cancer Inst 89:1683-91. 1997....- Population variations in the initial treatment of non-small-cell lung cancerArnold L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Blvd, EPN Room 4005, Bethesda, MD 20892, USA
J Clin Oncol 22:3261-8. 2004..We report the patterns of initial therapy focusing on the investigation of differences in receipt of recommended therapies according to multiple clinical and nonclinical patient characteristics... - Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancerArnold L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Clin Oncol 20:1192-202. 2002..Trends, patterns, and outcomes of adjuvant therapy for colorectal cancer, focusing on age, sex, and racial/ethnic differences, are reported... - Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes studyArnold L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, EPN Rm 4005, 6130 Executive Blvd, MSC 7344, Bethesda, MD 20892 7344, USA
J Natl Cancer Inst 96:1358-67. 2004..We present treatment-specific quality-of-life outcomes for prostate cancer patients 5 years after initial diagnosis... - Impact of screening on incidence and mortality of prostate cancer in the United StatesA L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, EPN Room 4005, 6130 Executive Blvd MSC 7344, Bethesda, MD 20892 7344, USA
Epidemiol Rev 23:181-6. 2001.... - Measuring complications of cancer treatment using the SEER-Medicare dataArnold L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland 20892 7344, USA
Med Care 40:IV-62-8. 2002..One category of outcomes amenable to research using Medicare claims is complications of cancer treatments: the unintentional, adverse side effects or sequelae of interventions used to treat or palliate cancer patients... - Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes StudyA L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA
J Clin Oncol 19:3750-7. 2001..To compare health-related quality-of-life outcomes after primary androgen deprivation (AD) therapy with orchiectomy versus luteinizing hormone-releasing hormone (LHRH) agonists for patients with prostate cancer... - Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes StudyA L Potosky
Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
J Natl Cancer Inst 92:1582-92. 2000..In this study, we compared the effects of two treatments on urinary, bowel, and sexual functions and on general health-related quality-of-life outcomes over a 2-year period following initial treatment... - The association between health care coverage and the use of cancer screening tests. Results from the 1992 National Health Interview SurveyA L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 7344, USA
Med Care 36:257-70. 1998..The authors investigated whether utilization of six different cancer screening tests (mammography, clinical breast exam, Pap smear, Fecal Occult Blood Test, and Digital rectal exam) varied according to type of health care coverage... - Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancerM L Brown
Applied Research Program, National Cancer Institute, Bethesda, Maryland 20892 7344, USA
Med Care 37:1249-59. 1999..This study develops estimates of long-term, cancer-related treatment cost using a modeling approach and data from the SEER-Medicare linked database. The method is demonstrated for colorectal cancer... - Comparison of self-reported initial treatment with medical records: results from the prostate cancer outcomes studyL X Clegg
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 8316, USA
Am J Epidemiol 154:582-7. 2001..These results can serve as a useful guide to researchers contemplating the use of surveys as an alternative to medical record abstraction to ascertain treatment in studies of patient outcomes... - Development of a comorbidity index using physician claims dataC N Klabunde
Health Services and Economics Branch, Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Executive Plaza North Room 4005, 6130 Executive Boulevard MSC 7344, Bethesda, MD, USA
J Clin Epidemiol 53:1258-67. 2000..The physician claims index can be used in conjunction with a comorbidity index derived from inpatient hospital claims, or employed as a stand-alone measure... - Cancer control-planning and monitoring population-based systemsJoe B Harford
Office of International Affairs, National Cancer Institute, EPN100, Bethesda, MD 20892, USA
Tumori 95:568-78. 2009..Experiences from around the world are reviewed to highlight the issues and showcase some possible solutions... - Identifying cancer relapse using SEER-Medicare dataCraig C Earle
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Med Care 40:IV-75-81. 2002..Linking administrative data to registry data, as in the creation of the SEER (Surveillance, Epidemiology, and End Results) and Medicare data set, can provide the ability to infer the occurrence of relapse in selected situations... - Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999Steven B Zeliadt
Department of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Urology 64:1171-6. 2004..To assess trends in the initial care of nonmetastatic prostate cancer, including the use of primary and adjuvant androgen deprivation therapy (ADT), using population-based treatment claims from 1991 to 1999... - Do patients consistently report comorbid conditions over time?: results from the prostate cancer outcomes studyCarrie N Klabunde
Health Services and Economics Branch, Applied Research Program, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland 20892 7344, USA
Med Care 43:391-400. 2005..Comorbidity is an important dimension of patient health status. However, limited attention has been given to assessing the reliability of patient-reported data on comorbid conditions... - 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes studyDavid F Penson
Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
J Urol 173:1701-5. 2005..In this study we assessed temporal changes in urinary and sexual function up to 5 years following radical prostatectomy in a population based cohort... - Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes StudyRobert A Stephenson
From the Division of Urology, University of Utah School of Medicine, Salt Lake City, Utah 8411132, USA
J Urol 174:646-50; discussion 650. 2005..We report use and treatment outcomes in a 5-year interval in a population based cohort from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study... - Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancerSteven B Zeliadt
Fred Hutchinson Cancer Research Center, Health Services Department, University of Washington School of Public Health and Community Medicine, Seattle, WA 98109 1024, USA
Int J Radiat Oncol Biol Phys 66:395-402. 2006..This study examines the effectiveness of adjuvant ADT combined with radiotherapy for a wide range of patients treated in the 1990s... - Should function and bother be measured and reported separately for prostate cancer quality-of-life domains?Bryce B Reeve
Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 7344, USA
Urology 68:599-603. 2006..The published results are mixed on reporting function and bother independently or together as a single domain... - Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancerDeirdre P Cronin
Surveillance Research Program, DCCPS, National Cancer Institute, Bethesda, Maryland, USA
Am J Gastroenterol 101:2308-18. 2006..Age disparities remain despite no evidence of greater chemotherapy-induced toxicity in the elderly. More equitable receipt of cancer treatment to all segments of the community will help to reduce mortality... - Trends in treatment costs for localized prostate cancer: the healthy screenee effectSteven B Zeliadt
Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Med Care 45:154-9. 2007..We sought to obtain estimates of trends in initial treatment costs during the prostate-specific antigen (PSA) era that account for the changing patient case-mix associated with screening... 
Population-based survivorship research using cancer registries: a study of non-Hodgkin's lymphoma survivorsNeeraj K Arora
Division of Cancer Control and Population Sciences, National Cancer Institute, 6130 Executive Blvd, MSC 7344, Executive Plaza North 4005, Bethesda, MD 20892 7344, USA
J Cancer Surviv 1:49-63. 2007..Drawing upon experiences from a study of survivors of non-Hodgkin's Lymphoma (NHL), we discuss conceptual and methodological challenges to and opportunities for conducting population-based survivorship research using cancer registries...- Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plansGerald F Riley
Office of Research, Development, and Information, Centers for Medicare and Medicaid Services, Baltimore, Maryland 21244, USA
Med Care 46:1108-15. 2008..To compare the Medicare managed care (MC) and fee-for-service (FFS) sectors on stage at diagnosis and treatment patterns for prostate, female breast, and colorectal cancers, and to examine patterns across MC plans... - Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controlsRichard M Hoffman
Medicine Service, New Mexico Veterans Affairs Health Care System, Albuquerque, NM 87108, USA
Cancer 101:2011-9. 2004..Prostate carcinoma and treatments affect health-related quality of life (HRQOL). The authors prospectively compared prostate and general HRQOL between prostate carcinoma cases and an age-matched and ethnicity-matched control group... - Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settingsJoan L Warren
Applied Research Program, National Cancer Institute, Executive Plaza North, Rm 4005, 6130 Executive Blvd, Bethesda, MD 20892 7344, USA
J Clin Oncol 20:307-16. 2002.... - General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes studyDavid F Penson
Section of Urology, VA Puget Sound Health Care System and the Department of Urology, University of Washington, Seattle, WA 98108, USA
J Clin Oncol 21:1147-54. 2003..The goal of this study was to determine the relationship between primary treatment, urinary dysfunction, sexual dysfunction, and general health-related quality of life (HRQOL) in prostate cancer... 
Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes studyRichard M Hoffman
Medicine Service, New Mexico VA Health Care System, Albuquerque, NM 87108, USA
J Gen Intern Med 18:845-53. 2003..We examined whether there were racial differences in initial treatment for clinically localized prostate cancer and investigated whether demographic, socioeconomic, clinical, or tumor characteristics could explain any racial differences...- Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancerVickie L Shavers
Applied Research Program National Cancer Institute, Bethesda, MD 20892, USA
J Gen Intern Med 19:146-55. 2004.... - Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancerVickie L Shavers
Applied Research Program, Health Services and Economics Branch, National Cancer Institute, Bethesda, MD 20892 7344, USA
Med Care 42:239-50. 2004..We examine the type and intensity of medical monitoring received by African American, Hispanic, and white patients with prostate cancer managed with "watchful waiting" in fee-for-service systems... - Comparing health care systems: the importance and limitations of outcome measuresArnold L Potosky
Med Care 40:359-61. 2002 - Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapyArnold L Potosky
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD
J Natl Cancer Inst 94:430-7. 2002..Therefore, men considering ADT as an initial treatment should be aware that sexual function and some aspects of physical well-being are likely to be affected in the first year following this treatment... - Latent variable modelling of recovery trajectories: sexual function following radical prostatectomyJulie M Legler
St Olaf College, Department of Mathematics, Northfield, MN 55057, USA
Stat Med 23:2875-93. 2004..The method is presented as a useful tool for identifying hypotheses associated with recovery and potential antecedents of importance... - Prostate-specific antigen test use reported in the 2000 National Health Interview SurveyLouie E Ross
Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341 3717, USA
Prev Med 38:732-44. 2004..In 2000, the National Health Interview Survey (NHIS) collected information about prostate-specific antigen (PSA) test use in a representative sample of U.S. men... - Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance ConsortiumJohn Z Ayanian
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
J Clin Oncol 22:2992-6. 2004 - Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USARichard M Hoffman
Medicine Service, New Mexico VA Health Care System, Albuquerque, New Mexico, USA
BMC Cancer 5:27. 2005..We compared patient characteristics and treatment selection between American men with screening-detected versus clinically diagnosed prostate cancers... - Incremental treatment costs in national cancer institute-sponsored clinical trialsDana P Goldman
RAND Health, 1700 Main St, Santa Monica, CA 90407 2138, USA
JAMA 289:2970-7. 2003..Concern about additional costs for direct patient care impedes efforts to enroll patients in clinical trials. But generalizable evidence substantiating these concerns is lacking... - Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes studyJulie N Graff
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
J Urol 177:1307-12. 2007..We determined which demographic and clinical factors predict overall and cancer specific survival with this treatment strategy in patients enrolled in the Prostate Cancer Outcomes Study... - Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes StudyRichard M Hoffman
Medicine Service, New Mexico VA Health Care System, Albuquerque, New Mexico 87108, USA
Cancer 97:1653-62. 2003.... - On the road to improving the quality of breast cancer care: a distance still to travelJeanne S Mandelblatt
Med Care 46:759-61. 2008